CBP-201
CBP-201-CN002
Phase 2 small_molecule completed
Quick answer
CBP-201 for Moderate-to-severe Atopic Dermatitis is a Phase 2 program (small_molecule) at Connect Biopharma Holdings Ltd with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Connect Biopharma Holdings Ltd
- Indication
- Moderate-to-severe Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed